Original Research Article

Comparison of Thrombolysis in Myocardial Infarction Score and Heart Score in risk stratification of acute myocardial infarction patients, prognostic accuracy and arrhythmia incidence

Keerthana Batyala*, M. V. Nagabhushana, Malli Dorasanamma

Department of Medicine, Narayana Medical College, Nellore, Andhra Pradesh, India

Received: 18 July 2019
Revised: 10 August 2019
Accepted: 14 August 2019

*Correspondence:
Dr. Keerthana Batyala,
E-mail: keerthana.batyala92@gmail.com

ABSTRACT

Background: To compare TIMI & HEART SCORE for their risk stratification in Acute Myocardial Infarction Patients, prognostic accuracy and Arrhythmia incidence.

Methods: This observational study is conducted in a Tertiary care hospital over a period of 2 years from August 2017 to July 2019. A total of 100 patients presented to ER with Chest Pain are selected for study. Patients were monitored for a period of one month in ICCU.

Results: In present study out of 61 cases with TIMI score ≥5, mortality of 11.5%(7 cases, p value 0.028). Heart score more than 6 constitutes high risk group, out of which mortality was observed in 7.45% cases (p=0.48). Most of the arrhythmias (70.49%) in present study observed in patients with TIMI score ≥5 (High risk group) which is statistically significant with p value 0.002. Most of the arrhythmias in present study observed in patients with HS ≥8 which is not statistically significant with p value 0.135.

Conclusions: In present study, overall mortality rate was 7% and these patients who died constitutes to high risk group with TIMI. HEART SCORE identified more patients as low risk compared to TIMI SCORE. TIMI SCORE is a good predictor of arrhythmia incidence.

Keywords: Thrombolysis in myocardial infarction score, Heart score, Risk stratification in acute myocardial infarction patients

INTRODUCTION

Risk stratification of Myocardial infarction patients is vitally important in the overall investigation and management of patients both acutely and long term. Risk stratification is particularly important during first 30 days after Acute Myocardial infarction, the period during which the risk of recurrent infarction and sudden death is greatest.

Over the past decade, a multitude of risk scores have been proposed to facilitate risk assessment. These scores are based on presenting clinical history and electrocardiographic and initial laboratory tests that enable early risk stratification on admission. One of the first validated and clinically useful risk scores was the Thrombolysis in Myocardial Infarction (TIMI) score for STEMI, derived from fibrinolytic therapy trials.¹

The Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) risk score uses both clinical and angiographic parameters.² The CADILLAC risk score can be calculated only after inter- pretation of angiographic
results and PCI, angio- graphic parameters included in the score have an important additive value to clinical variables.2

The TIMI risk score (2000) (Table 1) is derived from the Thrombolysis in Myocardial Infarction (TIMI)-11B trial, a multinational, randomized clinical trial, comparing unfractionated heparin to enoxaparin, which included all patients with confirmed ACS.3

| TIMI risk score for stemi | Points |
|--------------------------|--------|
| Historical               |        |
| AGE 65-75                | 2 Points |
| ≥ 75                     | 3 Points |
| DM/HTN or Angina         | 1 Point |
| Examination              |        |
| SBP < 100                | 3 Points |
| HR >100                  | 2 Points |
| Killip II - IV           | 2 Points |
| Weight < 67 KG           | 1 Point |
| Presentation             |        |
| Anterior STE or LBBB     | 1 Point |
| Time to rx > 4hrs        | 1 Point |
| Risk score = total       | (0-14) |

| Risk score | Odds of death by 30 days |
|------------|--------------------------|
| 0          | 0.1 (0.1-0.2)            |
| 1          | 0.3 (0.2-0.3)            |
| 2          | 0.4 (0.3-0.5)            |
| 3          | 0.7 (0.6-0.9)            |
| 4          | 1.2 (1.0-1.5)            |
| 5          | 2.2 (1.9-2.6)            |
| 6          | 3.0 (2.5-3.6)            |
| 7          | 4.8 (3.8-6.1)            |
| 8          | 5.8 (4.2-7.8)            |
| ≥8         | 8.8 (6.3-12)             |

Odds of death referenced to average mortality (95% confidence intervals).

The TIMI risk score for STEMI may be readily applied at the bedside at the time of hospital presentation and captures the majority of prognostic information offered by a full logistic regression model. This risk assessment tool is likely to be clinically useful in the triage and management of patients eligible for fibrinolytic therapy and may also serve as a valuable aid in clinical research.3,4 A dynamic risk score that can provide both an initial risk assessment and subsequent discharge reclassification could help clinicians to make decisions about the postdischarge care of STEMI patients. Physicians caring for patients post STEMI could use the dynamic TRS to inform frequency of follow-up and decide on the threshold for a monitored trial of treatment withdrawal. The risk-benefit ratio for the use of therapeutic devices and drugs varies with a patient’s estimated mortality and morbidity.3,4

The HEART risk score (Table 2) was developed for risk stratification of chest pain patients presenting to the ED. It quickly identifies both a large proportion of low-risk patients, in whom early discharge without additional testing goes with a risk of MACE of only 1.7%, and high-risk patients who are potential candidates for early invasive strategies.5 Utilization of the HEART score provided excellent determination of risk for 30- day MACE, comparing well with the TIMI score.6

| Clinical history and lab criteria | Points |
|----------------------------------|--------|
| History                          |        |
| High suspicious                  | 2 points |
| Moderately suspicious            | 1 point |
| Slightly or non-suspicious       | 0 point |
| ECG                              |        |
| Significant ST-depression         | 2 points |
| Non-specific repolarisation      | 1 point |
| Normal                           | 0 point |
| Age                              |        |
| ≥ 65 years                       | 2 points |
| > 45 - < 65 years                | 1 point |
| ≤ 45 years                       | 0 point |
| Risk factors                     |        |
| ≥ 3 Risk factors or history of CAD | 2 points |
| 1 or 2 Risk factors              | 1 point |
| No Risk factors                  | 0 point |
| Troponin                         |        |
| ≥ 3x Normal limit                | 2 points |
| > 1 x 3x Normal limit            | 1 point |
| ≤ Normal limit                   | 0 point |

Risk factors: DM, current or recent (<one month) smoker, HTN, HLP, family history of CAD, and obesity.
Score 0 - 3: 2.5% MACE over next 6 weeks→ Discharge Home.
Score 4 - 6: 20.3% MACE over next 6 weeks→ Admit for Clinical Observation.
Score 7 - 10: 72.7% MACE over next 6 weeks→ Early Invasive Strategies.

The Global Registry for Acute Coronary Events (GRACE) score, based on a large registry of patients across the spectrum of acute coronary syndromes (ACS) incorporates clinical and electrocardiographic characteristics to determine risk. The GRACE risk score was shown to be of predictive value for all forms of ACS.7 The CADILLAC and TIMI risk scores had high predictive value for mortality in hospital and at 1 year. The CADILLAC risk score was superior to the GRACE and TIMI risk score for MACE in hospital.8

The TIMI risk score is an easy to use tool and its use should be primarily for predicting risk of very near-term events. The CADILLAC score is not useful in the decision making before angiography; however, it is very useful for pre-dicting risk in patients undergoing PCI for ACS. The GRACE risk score can be used for all types of ACS patients in clinical practice.8

Comparing the composition of the three risk scores, all included the components of age and Killip’s classification, consistently shown to be important predictors of survival in patients with STEMI9,10.
The risk of MACE in patients with a HEART score ≤3 is 0.9%, 12% in patients with HEART score 4-6 and 65% in patients with a HEART score ≥7. The risk of death during the first 30 days after a STEMI in the literature was highest in patients who presented with advanced age, raised biomarkers, and high Killip class. Knowledge of the highest risk period for patients after PCI for STEMI will guide the clinician in structuring patient teaching, follow-up appointments, and diagnostic tests.

METHODS

This observational study is conducted in a Tertiary care hospital over a period of 2 years from August 2017 to July 2019. A total of 100 patients presented to ER with Chest Pain are selected for study. Patients were monitored for a period of one month in ICCU.

Inclusion criteria

- Patients 18 years of age or above presented to the emergency room with acute myocardial infarction.
- Myocardial infarction <48 hours old
- Presence of new on set Left Bundle Branch Block with rise of cardiac biomarkers.
- Presence of classical ECG changes of Hyperacute or Acute Myocardial infarction with transient rise in cardiac biomarkers.
- Presence of wall motion abnormality in 2D ECHO.
- Presence of pathological q-waves accompanied by ST-Segment elevation and Symmetrical T-Waves with rise in cardiac enzyme levels.

Exclusion criteria

- Patient is <18 years of age.
- Myocardial infarction 48 hours old or more.

A total of 100 patients were recruited on admission to the emergency room in tertiary care hospital. They include 78 males and 22 females. Patient with confirmed diagnosis of acute myocardial infarction and satisfying the inclusion and exclusion criteria were included in the study. All patients have been evaluated for risk factors like diabetes, alcohol, hypertension, hypercholesteremia and smoking. Risk stratification done by calculation TIMI SCORE and HEART SCORE.

Statistical analysis

The data has been entered into MS EXCEL and Statistical Analysis has been done using IBM SPSS Version 22.0 for Categorical variables, the data values are represented as number and percentages. To test the association between groups Chi-Square Test was used. For continuous variables, the data values are shown as Mean and Standard Deviation. All the P Values having less than 0.05 are considered as statistically significant.

RESULTS

Among the 100 patients, the maximum incidence of AMI in males was in 61-70 years of age group and in females it was in those who were older than 50 years.

There were only 10% cases below the age 40 years, and all were males. Overall, 78% cases were males and females constitute 22% of study (Figure 1).

![Figure 1: Age and gender incidence.](image)

In present study, majority of cases were smokers (53%), 50% of cases were hypertensive and 48% had diabetes and alcoholics constitutes 31% of the study (Figure 2).

![Figure 2: Risk factors associated with AMI.](image)

In present study 18 cases with AMI had comorbidities of which CKD (33.3%), CVA (33.3) constitutes the majority of cases. Hypothyroidism is seen in 11.1% of patients with AMI (Figure 3).

Most of the arrhythmias (70.49%) in present study observed in patients with TIMI score ≥5 (High risk group) which is statistically significant with P value 0.002 (Table 3).
The TIMI risk score (2000) is derived from the Thrombolysis in Myocardial Infarction (TIMI)-11B trial, a multinational, randomized clinical trial, comparing unfractionated heparin to enoxaparin, which included all patients with confirmed ACS. In a study done by Benjamin Sun et al, HEART SCORE is more accurate than TIMI and specifically outperforms TIMI at “Low-Risk” Thresholds. In another study by William Brady et al, HEART SCORE was more likely to classify patients as low risk and safe for discharge compared to clinical GESTLAT (20% Vs 13.5%). Christopher Byrne et al, have done a META-Regression analysis which revealed a strong linear relation between TIMI Risk score (p < 0.001) and the Cumulative incidence of Cardiac events.

Maureen Chase et al, stated “patient with the lowest risk as defined by a TIMI SCORE of zero had 1.7% incidence of adverse events. Therefore, the TIMI SCORE should not be used in isolation to determine disposition of patients presenting with chest pain”.

DISCUSSION

Table 6: Association between HS and mortality.

| HS | Discharge | Death | Total |
|----|-----------|-------|-------|
| 4 - 6 | 6 (100.0%) | 0 (0.0%) | 6 (6.0%) |
| 7 - 10 | 87 (92.55%) | 7 (7.45%) | 94 (94.0%) |
| Total | 93 (93.0%) | 7 (7.0%) | 100 (100.0%) |

Chi-square value = 0.49, p value = 0.488 (Not Sig.).

In present study out of 61 cases with TIMI score ≥5, mortality of 11.5% (7 cases) which is statistically significant with p value 0.028 (Table 5).

In present study majority of patients with AMI had Heart score more than 6 and constitutes high risk group, out of which mortality was observed in 7.45% cases, this association was found statistically not significant (Table 6).

REFERENCES

1. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005;45(9):1397-405.
2. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an Intravenous nPA for Treatment of Infarcting Myocardium II trial sub study. Circulation. 2000;102(17):2031-7.

3. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;283(7):835-42.

4. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17(17):1923-42.

5. Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008;16(6):191-6.

6. Six AJ, Cullen L, Backus BE, Greenslade J, Parsonage W, Alodus S, et al. The HEART score for the assessment of patients with chest pain in the emergency department: a multinational validation study. Crit Pathw Cardiol. 2013;12(3):121-6.

7. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP et al. Global Registry of Acute Coronary Events Investigators. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345-53.

8. Scruth EA, Cheng E, Worrall-Carter L. Risk score comparison of outcomes in patients presenting with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur J Cardiovasc Nurs. 2013;12(4):330-6.

9. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality I in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995;91(6):1659-68.

10. DeGeare VS, Boura JA, Grines LL, O'Neill WW, Grines CL. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2001;87(9):1035-8.

11. Backus BE, Six AJ, Kelder JC, Mast TP, van den Akker F, Mast EG, et al. Chest pain in the emergency room: a multicenter validation of the HEART score. Crit Pathw Cardiol. 2010;9(3):164-9.

12. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observation study (GRACE). BMJ. 2006;332(7578):1091.

13. Sun B, Laurie A, i*trACS investigators. Abstract 13647: Comparison of the HEART AND TIMI RISK SCORES for suspected acute coronary syndrome in the emergency department. Circulation. 2015;132:A13647.

14. Brady W, Souza K. The HEART SCORE: A guide to its application in the emergency department. Turk J Emerg Med. 2018;18(2):47-51.

15. Byrne C, Toarta C, Holt T. The HEART SCORE in predicting major adverse cardiac events in patients presenting to the emergency department with possible acute coronary syndrome: protocol for a systematic review and META – Analysis. 2018:7.

16. Chase M1, Robey JL, Zugby KE, Sease KL, Shofer FS, Hollander JE. Prospective validation of the Thrombolysis in myocardial infarction risk score in the emergency department chest pain population. Ann Emerg Med. 2006;48(3):252-9.

Cite this article as: Batyala K, Nagabhushana MV, Dorasanamma M. Comparison of Thrombolysis in Myocardial Infarction Score and Heart Score in risk stratification of acute myocardial infarction patients, prognostic accuracy and arrhythmia incidence. Int J Res Med Sci 2019;7:3300-4.